Mitchell Judith E, Hellkamp Anne S, Mark Daniel B, Anderson Jill, Johnson George W, Poole Jeanne E, Lee Kerry L, Bardy Gust H
JACC Heart Fail. 2013 Feb;1(1):48-55. doi: 10.1016/j.jchf.2012.10.004.
The aim of this study was to investigate whether patients with systolic heart failure (HF) and abnormal thyroid function are at increased risk for death.
Thyroid hormone homeostasis is vital to the optimal functioning of the cardiovascular system, but an independent prognostic effect of thyroid abnormalities in patients with HF has not been established.
In SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), which randomized patients with ischemic or nonischemic HF to placebo or amiodarone or implantable cardioverter-defibrillator therapy, thyroid-stimulating hormone (TSH) was measured at baseline and at 6-month intervals throughout the 5-year study.
Of 2,225 patients, the majority (87%) had normal TSH levels (0.3 to 5.0 μU/ml) at baseline, 12% had values suggestive of hypothyroidism, and 1% had values consistent with hyperthyroidism. Compared with euthyroid patients, those hypothyroid at baseline were older and included more women and Caucasians (all p values <0.05). Over the median follow-up period of 45.5 months, among patients euthyroid at baseline, 89 developed abnormally low TSH levels, and 341 developed abnormally high values. Patients randomized to amiodarone (median dose 300 mg) had an elevated risk for developing abnormal TSH levels compared with implantable cardioverter-defibrillator therapy or placebo (p < 0.0001). Patients with baseline or new-onset abnormal thyroid function had a higher mortality than those with normal thyroid function, even after controlling for other known mortality predictors (hazard ratio: 1.58; 95% confidence interval: 1.29 to 1.94; p < 0.0001 for hypothyroid; hazard ratio: 1.85; 95% confidence interval: 1.21 to 2.83; p = 0.0048 for hyperthyroid). Implantable cardioverter-defibrillator benefit did not vary with thyroid function.
Abnormal thyroid function in patients with symptomatic HF and ejection fractions ≤35% is associated with significantly increased risk for death, even after controlling for known mortality predictors.
本研究旨在调查收缩性心力衰竭(HF)且甲状腺功能异常的患者死亡风险是否增加。
甲状腺激素稳态对心血管系统的最佳功能至关重要,但HF患者甲状腺异常的独立预后影响尚未确定。
在心力衰竭猝死试验(SCD-HeFT)中,将缺血性或非缺血性HF患者随机分为接受安慰剂、胺碘酮或植入式心脏复律除颤器治疗,在为期5年的研究中,于基线及此后每6个月测量一次促甲状腺激素(TSH)。
2225例患者中,大多数(87%)在基线时TSH水平正常(0.3至5.0 μU/ml),12%的患者TSH值提示甲状腺功能减退,1%的患者TSH值符合甲状腺功能亢进。与甲状腺功能正常的患者相比,基线时甲状腺功能减退的患者年龄更大,女性和白种人更多(所有p值均<0.05)。在45.5个月的中位随访期内,基线时甲状腺功能正常的患者中,89例出现TSH水平异常降低,341例出现TSH水平异常升高。与植入式心脏复律除颤器治疗或安慰剂相比,随机接受胺碘酮治疗(中位剂量300 mg)的患者出现TSH水平异常的风险升高(p<0.0001)。即使在控制了其他已知的死亡预测因素后,基线或新发甲状腺功能异常的患者死亡率仍高于甲状腺功能正常的患者(风险比:1.58;95%置信区间:1.29至1.94;甲状腺功能减退患者p<0.0001;风险比:1.85;95%置信区间:1.21至2.83;甲状腺功能亢进患者p=0.0048)。植入式心脏复律除颤器的获益不受甲状腺功能的影响。
有症状的HF且射血分数≤35%的患者,即使在控制了已知的死亡预测因素后,甲状腺功能异常仍与显著增加的死亡风险相关。